Novartis Q3 Results and Pipeline Progress
Novartis, an innovative medicines company, delivers solid sales and core operating income growth with strong pipeline progress in Q3.
The company reaffirms its FY 2025 guidance, working to reimagine medicine and improve people's lives, with its medicines reaching 296 million people worldwide.
Company Overview
Novartis provides information and resources for patients, caregivers, and healthcare professionals, including clinical trial recruiting and funding opportunities.
- Clinical trial recruiting
- Managed access programs
- Funding opportunities for patient organizations
- Side effects reporting
Sustainability and Governance
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
Our medicines reach 296 million people worldwide.
Explore the Novartis in Society Integrated Report to learn more about the company's commitments to environmental, social, and governance.
Author's summary: Novartis delivers solid Q3 results.
More News
- MLB: The Last 10 World Series MVPs
- UPS: Q3 Earnings Snapshot - WTOP News
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Exploring the Flawlessness of Nature - Blood: River of Red Gold
- Importing beef is not the solution | GABEL
- Would you board an AI-piloted airliner?
- Kenya: Ten Years On, Odemba Dreams of Taking Starlets Back to Continental Table
- Elon Musk's xAI Launches Grok-powered 'Grokipedia' Encyclopedia
- The United States Is Broke. Americans May Not Care - But the World Does - The Heartland Institute
- BIMZELX® (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spon